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Two major pitfalls have hampered a confident prognostic use of CD38 expression: (1) the discordance about which cutoff value discriminates CD38
þ from CD38 À cases in defining the prognosis of individual patients; (2) the possibility that CD38 expression may vary over time raising the suspicion that CD38 may be an unstable, hence unreliable, marker.
The two issues are related as the definition of variation is strictly dependent on what one considers positive and negative at first. The point is not whether CD38 expression fluctuates with time, rather whether such variation may modify the prediction of the patient's prognosis at any given time, that is, whether a case previously defined positive may become negative or positive if previously negative. Several publications are equally distributed among reports of changes in the marker expression [1] [2] [3] [4] [5] ( Table 1a) and reports of an overall stability over time [6] [7] [8] [9] [10] (Table 1b) .
We compared CD38 expression on peripheral blood leukemic B cells from 111 CLL patients in at least two different moments of their disease (range 2-10 determinations), with a minimum of 6 month to a maximum of 113 month interval from the first determination (mean value 32 months). Following the general agreement, 6 differences p10% were ignored. In 99/111 cases, no variations could be detected in both untreated (76 cases) and treated (23 cases) patients. A total of 12 cases (four untreated, eight treated) showed a variation 410% at different time points (Figure 1a and b) . In all cases, a proportion of cells was CD38
þ at the time of the first determination (minimum 7%; maximum 100% CD38 þ cells). None of these In all, 10 cases showed differences 410% in CD38 expression, but only in three cases the changes crossed the considered cutoff value (30%), thereby modifying the prognostic risk.
d bim: bimodal expression of the CD38 marker, as described in Ghia et al.
9
NR: data not reported. NS: cases not specified.
cases became homogeneously CD38 À during the follow-up. Conversely, none of the CD38 homogeneously negative patients of our series (64 cases) acquired any expression of CD38 over time. A potential role of chemotherapy in modifying CD38 expression is suggested by the observation that a higher proportion of treated patients (8/31: 25.8%) as compared to the untreated (4/80: 5.0%) showed a change in CD38 expression. Nevertheless, no clear pattern of CD38 modifications following treatment was evident and irrespective of the type of treatment and patient's response (Figure 1b) .
Previous publications 1-5 described several patients who modified their CD38 expression over time. However, if one considers the actual percentages reported in three of those papers, 1,2,5 few patients would have changed their prognostic evaluation (Table 1a showed changes crossing the 30% 1,5 or 20% 2 cutoff values considered in those papers and therefore would have modified the prognostic risk. Interestingly, also these cases expressed some levels of CD38 at the time of the first determination (minimum 4%; maximum 42% CD38 þ cells) and none of them became homogeneously CD38
À during the follow-up 1,2,5 (Table 1a) . We analyzed our new series of 111 CLL patients utilizing any of the proposed cutoff values for CD38 expression 2,3,6,9
It appears that only five cases would change prognostic class if using the 'classic' 30 or 20% threshold, 2, 6 and none if considering the presence of 47% 3 or of any percentage 9 of CD38 þ cells within the leukemic population as a discriminator for positive cases (Figure 1a and b) . This indicates that even using the most stringent parameters, CD38 expression would be unreliable at diagnosis only in a tiny minority of cases (5/111:4.5%). Similar levels of infidelity also occur if the prognosis is based on the IgV H mutational status considering those cases with a percentage of somatic mutations between 97 3 and 98%, 1,6 who in our series of 98 sequenced patients are three (3.1%).
According to these evidences, the following conclusions can be drawn:
(1) CD38 expression may vary during the clinical course of CLL. (2) These changes do not modify the overall prognostic prediction made at diagnosis. In particular, the status of being homogeneously negative for CD38 expression, regardless the cutoff value considered, appears to be in all published works, as well as in our current series, a stable prognostic marker. (3) The role of chemotherapy and the predictive role of CD38 after remission need to be further explored as currently available treatments make molecular eradication possible. 9 Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G et al. Chronic myelomonocytic leukemia (CMML) is characterised by a persistent peripheral blood monocytosis (above 1 Â 10 9 /l) and the absence of a Philadelphia (Ph) chromosome (and BCR-ABL fusion gene). Molecular analysis of the Ph chromosome, identified in more than 95% of patients with chronic myeloid leukemia (CML), has shown that, according to the breakpoints in chromosome 22, the translocation t(9;22)(q34;q11) gives rise to a diversity of BCR-ABL fusion proteins involved in the pathogenesis of the disease (Figure 1a ). Most CML patients express the BCR-ABL transcript with the junctions b3a2 (e14a2) or b2a2 (e13a2) corresponding to the major BCR gene breakpoint cluster region (M-bcr). A few CML patients express a shortened BCR-ABL transcript with an e1a2 junction (m-bcr) and only sporadic cases express the rare junctions b2a3, b3a3 1 or e19a2 (m-bcr). Interestingly, most of these rare CML cases are associated with a particular clinical phenotype (a significant monocytosis for e1a2 junction 2-3 and a clinical picture of neutrophilic-CML for the e19a2 junction 4 ). These various CML clinical phenotypes with an e1a2 and e19a2 junctions raise the question of whether different forms of the BCR-ABL protein (heterogeneous by their BCR domain contribution) have intrinsically different leukemogenic activities in hematopoietic cells and may influence the clinical features of the disease entity ( Figure 1a) . Another atypical BCR-ABL transcript with an e6a2 junction (between e1a2 and b2a2 junctions) has only been described in four CML patients to date.
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5-8 None of these cases showed associated monocytosis or additional chromosomal abnormalities. The clinical and hematologic features of these previously reported cases have been recently reviewed and according to the authors could be associated with a worse prognosis.
8 In this paper, we report for the first time to our knowledge, a CMML patient, Philadelphia negative at diagnosis, who acquired this translocation along the course of the disease. Molecular studies allowed us to identify and quantify a rare transcript, the e6a2 BCR-ABL fusion mRNA in this CMML case.
A 64-year-old female patient was referred to our department in July 2001 for a thrombocytosis at 622 Â 10 9 /l and a monocytosis at 1.9 Â 10 9 /l discovered on a systematic peripheral blood analysis. Other leukocyte subsets counts and hemoglobin level were normal. Hepatosplenomegaly and lymphadenopathy were absent. At that time, the bone marrow morphology was considered as normal. A second bone marrow aspirate performed on March 2002 displaying myelodysplastic features associated with 15% of monocytes, The BCR-ABL junctions from leukemic cells of the CMML patient and positive controls (b3a2 and e1a2) were amplified using the LightCycler t(9;22) quantification kit (Roche Diagnostics). The e6a2 transcript was shown by the electrophoresis of an aliquot (10 ml) from positive PCR products. M ¼ 50-1000 bp molecular weight marker (Cambrex, Walkersville, MD, USA).
